Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...

We recently published an article titled Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

Highlights,The New York State Common Retirement Fund raised its stake in ImmunityBio by 62.8% in the fourth quarter.,Several ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

Full Year 2024 Results Key Financial Results Revenue: US$14.7m (up by US$14.1m from ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) traded up 6.8% on Tuesday following a better than expected earnings announcement. The stock traded as high as $3.01 and last traded at $3.05.

Reports Q4 revenue $7.55M, consensus $9.51M. “The first quarter of 2025 has been an inflection point for the Company with multiple milestones ...

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $30.00 target price ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code ...

ImmunityBio, Inc.’s IBRX share price has surged by 15.03%, which has investors questioning if this is right time to sell.